Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;223(2):96-101.
doi: 10.1159/000176190. Epub 2008 Nov 26.

Electron therapy for orbital and periorbital lesions using customized lead eye shields

Keiji Hayashi  1 , Kunito Hatsuno, Ryo-ichi Yoshimura, Toshiaki Iida, Fumio Ayukawa, Kazuma Toda, Hisashi Taniguchi, Hitoshi Shibuya
Affiliations

Electron therapy for orbital and periorbital lesions using customized lead eye shields

Keiji Hayashi et al. Ophthalmologica. 2009.

Abstract

Purpose: To establish the protective efficacy against late complications of electron therapy using customized lead eye shields in cases with orbital and periorbital lesions.

Methods: Between 1982 and 2006, 16 patients with 22 orbital and periorbital lesions were treated by electron therapy. Customized lead eye shields were prepared and placed in the respective patients' eyes during each fraction of electron therapy. The toxicity and local control rates were analyzed.

Results: The preparation period for the customized lead eye shields was 2 days. The shields could be used throughout the treatment period in all the patients. No evidence of radiation cataract was observed in 15 of the 16 patients. None of the patients developed corneal ulceration or evidence of lead poisoning.

Conclusion: Customized lead eye shields could be made relatively quickly, and electron therapy for orbital and periorbital lesions could be undertaken safely without any late complication.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The preparation of the lead eye shield. a Impression of the eye surface. b Lead eye shield (frontal view). c Lead eye shield (side view).
Fig. 2.
Fig. 2.
Schema of shielding eye.
Fig. 3.
Fig. 3.
Central axis dose curve of 4MeV electron. Relative ionization of the surface of the globe was 3.3% when the depth along the beam axis was 7 mm.
Fig. 4.
Fig. 4.
The 4MeV electron therapy process (35 Gy/14 fr/25 days) in a 26-year-old male with MALT lymphoma. a Lymphoma of the right inner canthus (white arrow). b Application of the lead eye shield during the electron therapy. c Electron therapy in progress. d The tumor vanished by 2.5 years after the electron therapy.
See this image and copyright information in PMC

Comment in

  • Ophthalmologica at a glance.
    Kroll P. Kroll P. Ophthalmologica. 2009;223(2):77. doi: 10.1159/000201561. Epub 2009 Feb 12. Ophthalmologica. 2009. PMID: 19212146 No abstract available.

References

    1. Asbell SO, Siu J, Lightfoot DA, Brady LW. Individualized eye shields for use in electron beam therapy as well as low-energy photon irradiation. Int J Radiat Oncol Biol Phys. 1980;6:519–521. - PubMed
    1. Jereb B, Lee H, Jakobiec FA, Kutcher J. Radiation therapy of conjunctival and orbital lymphoid tumors. Int J Radiat Oncol Biol Phys. 1984;10:1013–1019. - PubMed
    1. Smitt MC, Donaldson SS. Radiotherapy is successful treatment for orbital lymphoma. Int J Radiat Oncol Biol Phys. 1993;26:59–66. - PubMed
    1. Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys. 2002;54:818–823. - PubMed
    1. Lee SW, Suh CO, Kim GE, Yang WI, Lee SY, Hahn JS, Park JO. Role of radiotherapy for primary orbital lymphoma. Am J Clin Oncol. 2002;25:261–265. - PubMed

LinkOut - more resources